MA24215A1 - Composes inhibiteurs de squalene-synthetase - Google Patents

Composes inhibiteurs de squalene-synthetase

Info

Publication number
MA24215A1
MA24215A1 MA24667A MA24667A MA24215A1 MA 24215 A1 MA24215 A1 MA 24215A1 MA 24667 A MA24667 A MA 24667A MA 24667 A MA24667 A MA 24667A MA 24215 A1 MA24215 A1 MA 24215A1
Authority
MA
Morocco
Prior art keywords
squalene
inhibitor compounds
synthetase inhibitor
synthetase
compounds
Prior art date
Application number
MA24667A
Other languages
English (en)
Inventor
Seiichi Hamanaka Ernest
Myers Hayward Cheryl
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA24215A1 publication Critical patent/MA24215A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
MA24667A 1996-06-20 1997-06-18 Composes inhibiteurs de squalene-synthetase MA24215A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2236596P 1996-06-20 1996-06-20

Publications (1)

Publication Number Publication Date
MA24215A1 true MA24215A1 (fr) 1997-12-31

Family

ID=21809221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24667A MA24215A1 (fr) 1996-06-20 1997-06-18 Composes inhibiteurs de squalene-synthetase

Country Status (8)

Country Link
US (1) US6537987B1 (fr)
AP (1) AP9701018A0 (fr)
AU (1) AU2401697A (fr)
GT (1) GT199700069A (fr)
ID (1) ID19419A (fr)
MA (1) MA24215A1 (fr)
TN (1) TNSN97105A1 (fr)
WO (1) WO1997048701A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0862562T3 (da) * 1995-09-13 2001-09-24 Takeda Chemical Industries Ltd Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler
US20060141036A1 (en) 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
JP2002501887A (ja) * 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
EP1407782A4 (fr) * 2001-06-28 2004-10-20 Takeda Chemical Industries Ltd Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes
WO2003043624A1 (fr) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Inhibiteurs doubles de la proteine de liaison des acides gras des adipocytes et de la proteine de liaison des acides gras des keratinocytes
AU2003231252A1 (en) * 2002-05-09 2003-11-11 Enos Pharmaceuticals, Inc. Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DE102004001871A1 (de) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclische Benzazepin-Derivate und ihre Verwendung
DE102004006325A1 (de) * 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
US7323455B2 (en) 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
WO2006016681A2 (fr) * 2004-08-09 2006-02-16 Takeda Pharmaceutical Company Limited Agent de reduction de la crp
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076598A2 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Composes heterocycliques bicycliques en tant que modulateurs des recepteurs de canabinoides
WO2006076569A2 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques servant de modulateurs aux recepteurs cannabinoides
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (fr) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones utilisees comme modulateurs de la 5ht
CN101277949A (zh) * 2005-04-22 2008-10-01 阿兰托斯制药控股公司 二肽基肽酶-ⅳ抑制剂
TW200714280A (en) * 2005-06-01 2007-04-16 Takeda Pharmaceuticals Co Novel method of treating hyperlipidemia
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
TW200730503A (en) * 2005-10-21 2007-08-16 Daiichi Seiyaku Co Tricyclic compound
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
DE102006031176A1 (de) * 2006-07-06 2008-01-10 Bayer Healthcare Ag Substituierte Benzoxepino-isoxazole und ihre Verwendung
FR2904002A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
SG174504A1 (en) 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
EP2892896B1 (fr) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Antagonistes du récepteur 1 de l'hormone de concentration de pyrrolone ou pyrrolidinone mélanine
EP2892897A1 (fr) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Antagonistes du récepteur 1 d'hormone concentrant la mélanine de type pyrrolone ou pyrrolidinone
CN106543102B (zh) * 2016-10-28 2018-09-14 石家庄学院 1,5-苯并硫氮杂卓类衍生物及其应用
WO2020016335A1 (fr) 2018-07-19 2020-01-23 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
CN118666865A (zh) * 2023-03-17 2024-09-20 中山大学 手性或消旋的嘧啶并七元氧氮杂环类化合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332792T2 (de) * 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
MX9702175A (es) * 1994-09-20 1997-06-28 Pfizer Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
JPH10500702A (ja) * 1994-12-23 1998-01-20 ファイザー・インコーポレーテッド スクアレンシンテターゼ阻害剤としてのナフチル−ベンゾキサゼピンまたは−ベンゾチアゼピン
DK0862562T3 (da) * 1995-09-13 2001-09-24 Takeda Chemical Industries Ltd Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors

Also Published As

Publication number Publication date
US6537987B1 (en) 2003-03-25
TNSN97105A1 (fr) 2005-03-15
WO1997048701A1 (fr) 1997-12-24
AP9701018A0 (en) 1997-07-31
GT199700069A (es) 1998-11-24
AU2401697A (en) 1998-01-07
ID19419A (id) 1998-07-09

Similar Documents

Publication Publication Date Title
ID19403A (id) Senyawa-senyawa heterosiklik
ID19609A (id) Senyawa-senyawa heterosiklik
ID16152A (id) Senyawa-senyawa triaril
ID19430A (id) Senyawa senyawa heterosiklik
BR9709230A (pt) Composto
ID15904A (id) Senyawa-senyawa tiofenopirimidina
GT199700069A (es) Compuestos inhibidores de la escualeno sintetasa
BR9707051A (pt) Composto
ID19476A (id) Senyawa piridilpirol
PT958287E (pt) Inibidores de sulfamida-metaloprotease
ATE262512T1 (de) Arylalkanoylpyridazine
ID18685A (id) Senyawa trisiklik tersubstitusi
DE69716924D1 (de) Phosphonat-nukleotid-verbindungen
BR9707514A (pt) Inibidor de neovascularizacão
BR9705635A (pt) Compostos
ATE353652T1 (de) Östroprogestatives antikonzeptionsmittel
DE69714228D1 (de) Kristalline metallophosphate
BR9711205A (pt) Composto
PT923594E (pt) Compostos de bromotiacumicina
DK0923562T3 (da) Substituerede p-trifluormethylphenyluraciler
DE69709659D1 (de) Halopropargyl-einschlussverbindungen
DE59707428D1 (de) Substituierte 1-methyl-3-benzyluracile
ATE275146T1 (de) Substituierte pyrazol-3-ylbenzazole
DE59712222D1 (de) Substituierte phenyluracile
DE59708674D1 (de) Substituierte 3-phenylpyrazole